Dr. Kelly on the JAVELIN Solid Tumor Trial

Karen Kelly, MD
Published: Friday, Apr 22, 2016



Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of the phase Ib JAVELIN Solid Tumor Trial.

This international trial has multiple expansion cohorts with a 3+3 design, Kelly explains. The trial set the 10 mg/kg bi-weekly dose of avelumab as the recommended phase II dose, before going onto 16 selected to solid tumor cohorts. In the phase Ib analysis, a safety update of avelumab was examined in the first 900 patients.

Results showed that there were minimal differences in toxicity observed. Patients who were enrolled in the first-line non–small cell lung cancer cohort experienced slightly less toxicity versus patients in the other cohorts, she adds.



Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of the phase Ib JAVELIN Solid Tumor Trial.

This international trial has multiple expansion cohorts with a 3+3 design, Kelly explains. The trial set the 10 mg/kg bi-weekly dose of avelumab as the recommended phase II dose, before going onto 16 selected to solid tumor cohorts. In the phase Ib analysis, a safety update of avelumab was examined in the first 900 patients.

Results showed that there were minimal differences in toxicity observed. Patients who were enrolled in the first-line non–small cell lung cancer cohort experienced slightly less toxicity versus patients in the other cohorts, she adds.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x